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Purpose: To use specific parameters to evaluate the in vitro quality 
assurance of ten generics of amlodipine besylate (10mg) tablets commonly 
sold in the Nigerian drug market.  
Methods: Organoleptic and physicochemical properties of 10 brands of 
the amlodipine besylate tablets were assessed according to official and 
unofficial standards. Basic quality control parameters evaluated include 
uniformity of weight, uniformity of content, tablet friability, hardness test, 
disintegration and dissolution tests.  
Results: The results show that all the tablets passed the weight uniformity 
(mean tablet weights ranging from 155±003mg to 404±0.002 mg), 
friability < 5%, disintegration (< 4 mins) and dissolution tests (>70% 
released within 40 mins). While seven of the ten brands passed the 
uniformity of content, two out of the three brands that failed the test were 
unregistered by NAFDAC. The seven brands can be used interchangeably 
with the branded, Amlovar.  
Conclusion: The finding of this research further underscores the need for 
stakeholders and end users to insist on the use of only duly registered 
products by the regulatory body. 
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Medication cost is a chief determinant of the 
affordability and compliance to any treatment 
regimen. Branded drug products from the 
multinational companies are highly advertised 
and promoted through electronic media, hand 
bills, newspapers and printed matters [1]. There is 
a general belief that the more expensive and 
aggressively promoted a particular drug product 
is, the more effective and widely accepted the 
product. The long-term effect of these 
promotional strategies is the high cost of the 
medication and with a resultant effect of inability 
of the patient to afford the medication and hence 
poor compliance to treatment regimen [1]. In 
order to overcome these problems, efforts have 
been made to source for the unbranded drug 
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and are expected to be bio-equivalent to the 
branded. However, this has led to the 
overwhelming influx of so many generic products 
particularly from the Asian Pacific into many 
third World/Developing nations in African 
continent and particularly Nigeria [2]. Some of 
these drugs have been reported to be substandard, 
counterfeit and most often are cheaper in order to 
attract higher market patronage with the resultant 
implication (2). 
 
A counterfeit medicine as defined by the World 
Health Organization (WHO) is one that is 
deliberately and fraudulently formulated and/or 
mislabeled with respect to identity and/or source 
[3]. This is applicable to both branded and 
generic products and may include products with 
the correct ingredients or with the wrong 
ingredients, without active ingredients, 
insufficient active ingredients, with fake 
packaging. Previous studies revealed that the 
causes responsible for the availability of 
counterfeit drugs in Nigeria include inadequate 
laws, lack of implementation of existing laws by 
the drug law enforcement agencies, porosity in 
the National boarders, inability to afford the 
actual costs of drugs, poverty, ignorance and 
corruption [1]. Rapid influx of counterfeit and 
fake drugs has created some alarming fears and 
worries on the minds of the patients (the end 
users) and stakeholders over the years. Quality 
control parameters are important tools that can be 
used in assessing the genuine quality of content 
before their consideration for possible 
substitution and/or interchangeability of different 
multi-source brand of a drug [4].   
 
Amlodipine, a structurally related compound to 
nifedipine is a calcium channel blocker, which in 
addition to its anti-angina and anti arrhythmic 
effects also dilates peripheral arterioles and 
reduces blood pressure [5]. This multifaceted 
function in mediating cardiac activity has led to 
its popularity in terms of its wide acceptance and 
use in hypertension management. Again, 
amlodipine is well tolerated by majority of 
patients with very limited side effects. Its 
prolonged half-life (t
1/2
 of 35 – 50 hours) when 
administered at a dose of 10mg daily offers 
maximum convenience to the patient [5]. In order 
to enhance patients’ affordability of their 
medications, stakeholders have resorted to source 
for generics, which supposedly should contain the 
same amount of the active, as do, the expensive 
unaffordable brands. Previous workers [6,7] have 
emphasized the need to evaluate the in vitro 
pharmaceutical quality assurance of certain drugs 
e.g., quinine and ibuprofen, respectively. A 
search in the literature showed that in Nigeria, 
there has been no such in-vitro assessment of the 
pharmaceutical quality assurance of amlodipine; 
an anti-hypertensive drug with so many generics 
available for substitution for the brand Amlovar 
which is very expensive and unaffordable by the 







Samples of amlodipine tablets (10mg) of 
different generics were purchased from 
Pharmacies across three States in Nigeria 
(Anambra, Edo and Ondo) respectively. No 
particular sampling procedure was employed 
other than one of the researchers posing as a 
normal customer, purchased at least a minimum 
of 100 number of tablets of a particular generic 
without a prescription. The different brands were 
obtained from drug stores wherever they could be 
found until ten generic samples were collected. 
The pure amlodipine powder sample was 
received from Neimeth Pharmaceuticals Limited, 
Nigeria as a gift. All other reagents employed in 





Physical evaluation of the labels 
 
As part of the evaluation procedure, the ten 
generics were coded as “AM” and numbered 1 – 
10 for easy identification. Following the purchase 
of the samples, labeling informations such as 
manufacturer’s address and country of origin of 
the brands, batch numbers, manufacturing dates, 
labeled strength and registration status by the 
National Agency for Food and Drugs 
Administration and Control (NAFDAC) were  
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AM 1 Amlovar 90105004 Sep-09 Sep-12 10mg A4-0333 Nigeria 
AM2 Amlovasc C92565 Apr-08 Apr-11 10mg NIL Uk 
AM 3 Swivasc BV0901 Jan-09 Dec-10 10mg Aa2279 India 
AM4 Lofra EA0059A Nil Jan-11 10mg A40787 Portugal 
AM5 Novasc 910276631 NIL Jun-13 10mg 04-5354 Germany 
AM6 Cardipret ZN107901 Jul-09 Jun-12 10mg A4-2639 India 
AM7 Amlovasc 804211500 Apr-09 Apr—11 10mg A4-1338 Turkey 
AM8 Amlodipine OB15UH Nil Feb-15 10mg Nil Uk 
AM9 Asomex 01B09025 Nov-09 Oct.-11 10mg 04-9891 India 
AM!0 Amlosam 905 May-09 Apr-11 10mg A4-2447 India 
 
















AM1 White Hexagon PGU/10 & N 13 0.1 0.389±0.007 101.6 
AM2 White Oval R & 178 17 0.2 0.314±0.004 80 
AM3 Off white Round A & 10 136 0.3 0.129±0.004 97 
AM4 White Round MP & A/10 6 0.2 0.396±0.006 104.2 
AM5 White Octagon Amlo-10 & Pfizer 8 0 0.404±0.002 100.2 
AM6 Off white Oval Cadiprot 10 76 3.5 0.155±0.003 96.5 
AM7 White Round - 7 4.5 0.398±0.008 95.5 
AM8 White Round AB10 7 21.1 0.397±0.004 78.9 
AM9 Yellow Heart A & 5 11 21.4 0.103±0.003 78.6 
AM10 White Oval - 186 3.2 0.155±0.004 96.8 
 
recorded from the product labels where available 
(Table 1). 
 
Evaluation of the organoleptic properties of 
the tablets 
 
 Preliminary evaluation of the organoleptic 
properties of the tablets was carried out for all 
samples following purchases. The following 
parameters were evaluated: colour, shape of the 
tablet, taste, inscription, odour and coating types 
were analysed objectively by three different 
assessors and the decision of at least two 
assessors were considered valid and tabulated as 
shown in Table 2. 
 
Analysis of physicochemical properties of 
tablets 
 
The tablets were further assessed for uniformity 
of weight, disintegration time, content uniformity 
and dissolution rate according to B.P. 2003 [8]. 
Weight uniformity was carried out by 
determining the weight of twenty randomly 
selected tablets from each brand using a digital 
weighing balance (College B154, Mettler Toledo, 
Switzerland) while the disintegration time of six 
tablets per brand was determined in distilled 
water maintained at 37±0.5°C using Manesty 
Tablet Disintegration Apparatus (Manesty 
Machines, Liverpool, England). The dissolution 
profiles were carried out using dissolution test 
apparatus (Model: Caleva). This was fitted with a 
basket rotated at 100 rpm using 800 ml of 0.1M 
hydrochloric acid solution as dissolution medium 
maintained at 37±0.5
0
C. One tablet at a time from 
each brand was placed in the basket and lowered 
into the vessel containing the dissolution 
medium. A 5ml sample was withdrawn at various 
intervals and replaced with an equivalent volume 
maintained at same temperature 37±0.5°C of the 
dissolution medium. The sample was filtered and 
e105
Eichie et al                                                                                            Quality of Commercial Amlodipine Besylate 
 
Int J Health Res, March 2011; 4(1):    60 
diluted with an equal volume of 0.1M HCl. This 
was continued for 60 mins. The absorbance of the 
resulting solutions was measured at λmax. 238 nm, 
using UV/Visible spectrophotometer (PG 
instruments Ltd, model T70). The test was carried 
out in triplicates and mean values are reported.  
 
Results and Discussion 
 
The result of organoleptic properties of tablets is 
presented in Table 2. The tablets varied in shapes 
and surface inscriptions. The inscriptions 
appeared smooth and unbroken on the tablet 
surface (Table 2). They were all evenly coloured 
and whitish. They were all however, uncoated, 
odourless and tasteless. Tablet shapes and colours 
are used primarily for the physical identification 
of dosage forms, while inscriptions are written 
specifically to identify the tablet with its 
manufacturer. However, most tablets are white 
hence the need for further tests to validate their, 
properties.  The results of weight uniformity, 
disintegration time and percentage content are 
shown in table 2. The BP 2003 test for uniformity 
of tablet weight indicates that for tablets 
weighing 250 mg and over, the percentage 
deviation above average weight should be ±5%. 
All tablets fell within that limit and as such all the 
brands passed the uniformity of weight test with 
minimal deviations from their mean weights. 
Furthermore, the recommended disintegration 
time for uncoated tablets is less than 15 minutes 
while for coated tablets and capsules are 30 
minutes and as such all the brands passed the 
disintegration time. The highest disintegration 
time obtained was for AM10, which was 3 mins. 
This suggests that the tablets will disintegrate 
within the acceptable time of 15 mins. Friability 
is an unofficial test. It is designed to ascertain the 
ability of the tablets to withstand mechanical 
breakage due to vibrations associated with 
transportation and carriage. The results showed 
that with the exception of AM8 and AM9, the 
tablets were not friable as less than 5% was lost 
after operating the friabilator at 25 rpm for 4 
mins. The disintegration time of AM 4 was as 
low as 6 secs. The result showed that all the 
brands conformed to the BP requirement. The 
conformity of the brands to the BP specification 
for disintegration may be attributed to the 
appropriate use of disintegrants and other 
excipients like binders and lubricants by the 
manufacturers. The type of disintegrant used and 
the method of incorporation of the disintegrant 
could also affect the rapid release of the drug into 
solution. The implications of the disintegration 
and friability results are that drug manufacturers 
put in much effort to ensure that the dosage forms 
they manufacture meet and even exceed officially 
recommended standards. 
Figure 1: Percentage amount of amlodipine released 
from the different generic brands 
 
The uniformity of content test is the final test to 
determine the validity of a well-formulated 
product. The result of percentage content showed 
that AM 2, AM 8 and AM 9 had less than 80% 
content. Interestingly, AM2 and AM8, were not 
registered by the regulatory body in Nigeria. This 
may suggest the probability that the drugs were 
smuggled into the Country and hence they were 
regarded as fake and counterfeit drugs and are 
therefore not considered safe for consumption. 
Unfortunately, they found their way to the public. 
Dissolution test provides valuable in vitro data 
for the development of pharmaceuticals. The BP 
2003 [8] states that, 70% of the uncoated tablet 
drug should dissolve within 40 mins. All the ten 
brands released more than 70% of their contents 
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amount of the drug should be available for 
absorption to elicit the expected therapeutic effect 




All the brands of the amlodipine passed the 
uniformity of weight test, disintegration test. 
They were all within the acceptable limits of 
hardness. All brands displayed excellent 
dissolution profiles. Seven of the ten brands 
passed the content uniformity test. It can 
therefore be concluded that the seven brands are 
all within acceptable standards and show good 
quality and very importantly can be 
interchangeable with the innovator brand 
(Amlovar®) by Neimeth Pharmaceuticals Nigeria 
Ltd. The need to emphasize the use of only 
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